Navigation Links
Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
Date:10/29/2008

Co-founder of and Former Senior Executive at ImClone Brings Substantial Oncology Drug Development Expertise

NEW BRUNSWICK, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today the appointment of Harlan W. Waksal, M.D., 55 to its board of directors. Senesco's board of directors now consists of nine members, seven of whom are independent.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081029/NY42202 )

Dr. Waksal is the President and Sole Proprietor of Waksal Consulting L.L.C., which was founded in 2003 and provides strategic business and clinical development counsel to biotechnology companies. Dr. Waksal co-founded the biotechnology company, ImClone Systems Incorporated, in 1984. He served at ImClone in a variety of senior roles over a 16 year period, beginning in 1987. During his tenures as Chief Operating Officer, from 1987 through 2002, and Chief Executive Officer, from 2002 until 2003, Dr. Waksal was instrumental in moving forward the clinical development program for ERBITUX(R) (cetuximab), an oncology drug now approved in colorectal and head & neck cancers. ERBITUX (cetuximab) is a monoclonal antibody (IgG1 Mab) designed to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells, called the epidermal growth factor receptor (EGFR).

"Senesco is very pleased to have Dr. Waksal join our Board," said Rudolf Stalder, Chairman of Senesco's Board. "His significant contribution to the clinical development of Erbitux, and vast knowledge of the oncology space, will provide critical industry insight to Senesco."

"We look forward to working with Dr. Waksal as we move toward our goal of filing an IND for multiple myeloma," said Bruce Galton, President & Chief Executive Officer of Senesco. "We believe his extensive and distinguished work in the biotechnology industry will be a great resource in our oncology drug development efforts."

Dr. Waksal is the author of 50 published scientific papers, many in the area of oncology. He currently serves on a number of non-corporate boards, including the American Committee for the Weizmann Institute of Science in New York, NY, Oberlin College in Oberlin, OH and the Montclair Art Museum in Montclair, NJ. Dr. Waksal also serves on the Technology Advisory Board for the New Jersey Edison Innovation Fund.

He earned his B.A. in biology from Oberlin College in 1975, and received his M.D. from Tufts University School of Medicine, Boston, MA.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain diseases inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, our ability to maintain our continued listing standards for the next 12 months, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contacts: Investor Relations Contact:

Senesco Technologies, Inc. FD

Bruce Galton Brian Ritchie

Chief Executive Officer (brian.ritchie@fd.com)

(bgalton@senesco.com) (212) 850-5600

(732) 296-8400


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2. Senesco Technologies Announces Successful Completion of First Milestone Related to Agreement with Bayer CropScience
3. Senesco Technologies Closes Remaining $3.0 Million of Previously Announced Financing
4. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
5. Senesco Technologies to Present at BIO 2008 Business Forum
6. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
7. Senesco Technologies Regains Compliance With Amexs Continued Listing Requirements
8. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
9. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
10. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
11. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017  MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
(Date:2/23/2017)... ... February 23, 2017 , ... Baltimore ... multiple immunoassay-based threat detection technologies by researchers from the Pacific National Northwest ... detection technology was found to have the best level of detection (LOD) ...
(Date:2/23/2017)... Feb. 23, 2017 Aviva Systems Biology ... the acquisition of GenWay Biotech Incorporated, a protein ... and product offering for both the research and ... growth and enhance capabilities for both entities. GenWay,s 18 ... assays will nicely complement ASB,s objective to become ...
(Date:2/22/2017)... ... 22, 2017 , ... Park Systems , a leader in Atomic Force ... SPIE attendees and Park customers on Feb. 27, 2017 from 12-2pm at ... Convention Center. The luncheon will feature a talk on Automated AFM for Small-Scale ...
Breaking Biology Technology:
(Date:1/24/2017)... -- It sounds simple and harmless—an electronic sensor attached ... and alerts parents on their smart phones if, ... But pediatric experts argue that such devices may ... of medical benefits, especially to healthy babies. ... of healthy babies, promising peace of mind about ...
(Date:1/21/2017)... Research and Markets has announced the addition of the "Global ... ... recognition biometrics market to grow at a CAGR of 19.36% during ... scenario and the growth prospects of the global voice recognition biometrics ... the revenue generated from the sales of voice recognition biometrics including ...
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
Breaking Biology News(10 mins):